TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity
X. Wang, Q. Wang, W. Li, et. al.
J Exp Clin Cancer Res. 2020 May 24;39(1):93. doi: 10.1186/s13046-020-01595-x.
CARDIONCOLOGY.ORG ABSTRACT:
Though Doxorubicin is effective in a variety of malignancies, its use limited due to a cumulative dose-dependent cardiotoxicity. This preclinical study in zebrafish, mice and H9C2 cardiomyocytes aims to explore the anti-inflammation effects of Dihydrotanshinone I (DHT) on anti-doxorubicin-induced cardiotoxicity (DIC).
Results indicate that DHT can be applied as a novel cardioprotective compound in the anti-inflammation management of DIC.
© All Rights Reserved